List of Excipients in Branded Drug FLUMIST QUADRIVALENT

« Back to Dashboard

FluMist Quadrivalent Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

FluMist Quadrivalent is a live attenuated, intranasal influenza vaccine supplied as a preservative-free nasal spray. Its excipient system is designed to preserve viral infectivity, maintain spray performance, support storage stability, and tolerate administration across pediatric and adult populations. The strongest commercial opportunities are in needle-free vaccination, pharmacy and employer distribution, self- or caregiver-administration, reformulation for improved stability, and supply-chain simplification.

FluMist was developed by MedImmune, now part of AstraZeneca. The product is licensed under FDA biologics license application (BLA) 103782 and is not a conventional small-molecule drug listed through an NDA. The current commercial product has historically been the quadrivalent formulation, although seasonal influenza vaccine composition and product labeling may change as regulatory authorities move toward trivalent influenza vaccines.

What excipients are used in FluMist Quadrivalent?

FluMist Quadrivalent contains live attenuated influenza virus in a buffered, sugar-containing aqueous formulation. The FDA prescribing information identifies the following formulation components: sucrose, dibasic potassium phosphate, monobasic potassium phosphate, gelatin hydrolysate, arginine hydrochloride, monosodium glutamate, gentamicin sulfate, egg proteins, and water for injection.[1]

Component	Primary formulation role	Commercial or technical relevance
Sucrose	Stabilizes viral particles during storage and temperature variation	Low-cost, established vaccine stabilizer
Potassium phosphate, monobasic and dibasic	Maintains formulation pH	Supports viral infectivity and nasal tolerability
Gelatin hydrolysate	Protein stabilizer and cryoprotective excipient	May create dietary, religious, or allergy-related market constraints
Arginine hydrochloride	Protein and virus stabilizer; may reduce aggregation	Potential platform excipient for live-virus products
Monosodium glutamate	Stabilizer and bulking component	Familiar vaccine excipient with established regulatory history
Gentamicin sulfate	Residual manufacturing antibiotic	Can create labeling and hypersensitivity considerations
Egg proteins	Manufacturing residual from egg-based virus propagation	Limits positioning for some egg-allergic or egg-avoidant populations
Water for injection	Vehicle	Supports aqueous intranasal delivery

The product is preservative-free and delivered in a single-use 0.2 mL nasal sprayer. Each dose contains live attenuated influenza viruses representing four seasonal strains in the quadrivalent formulation.[1]

How does the FluMist excipient system support live attenuated virus stability?

FluMist requires a formulation that protects infectious virus rather than merely preserving a purified protein or chemically defined active ingredient. The formulation must maintain viral viability through manufacturing, filling, distribution, refrigerated storage, and administration.

Sugar stabilization

Sucrose is the principal low-molecular-weight stabilizer disclosed in the label. In live-virus formulations, sucrose can reduce structural damage caused by freezing, drying, concentration changes, and interfacial stress. It also helps maintain the physical environment around viral particles during refrigerated storage.

For follow-on products, sucrose is commercially attractive because it is inexpensive, widely available, compatible with aqueous processing, and supported by extensive vaccine precedent. The limitation is that sucrose alone is unlikely to create meaningful product differentiation. Its value lies in combination with buffer strength, protein stabilizers, container closure, and manufacturing controls.

Buffer selection

The monobasic and dibasic potassium phosphate system controls pH. Influenza virus infectivity is sensitive to pH, ionic strength, temperature, and repeated stress. A phosphate buffer is familiar to vaccine manufacturers and supports a relatively simple manufacturing process.

Potential improvement areas include:

• Lower buffer concentration to reduce nasal irritation.
• Alternative buffer systems with improved cold-chain stability.
• pH optimization for each seasonal strain combination.
• Reduced ionic strength to limit spray-device interactions.
• Buffer systems compatible with longer excursions outside refrigerated conditions.

Any replacement would require comparative studies showing equivalent or superior potency, stability, safety, and delivery performance.

Protein and amino-acid stabilization

Gelatin hydrolysate, arginine hydrochloride, and monosodium glutamate provide a broader stabilization system than sucrose and phosphate alone. These ingredients may limit aggregation, adsorption to container surfaces, and loss of infectivity during processing.

Arginine is particularly relevant to formulation developers because it is used in biologics to reduce aggregation and surface adsorption. Its concentration must be balanced against osmolality, nasal tolerability, and potential effects on viral infectivity.

Gelatin hydrolysate has a longer regulatory history in vaccines but creates commercial constraints. Certain consumers avoid porcine-derived materials for religious, dietary, or cultural reasons. A gelatin-free FluMist formulation could expand access in selected markets if it preserved potency and spray performance.

What formulation patents protect FluMist Quadrivalent?

Publicly available product labeling establishes the formulation composition and manufacturing description but does not, by itself, establish the scope or current enforceability of FluMist patent rights. FluMist is licensed as a biologic under BLA 103782 rather than as a conventional NDA product.[1]

The relevant intellectual-property categories include:

1. Live attenuated influenza virus strains and reassortant technologies.
2. Cold-adapted, temperature-sensitive, and attenuated virus phenotypes.
3. Reverse-genetics and virus rescue methods.
4. Seasonal strain selection and manufacturing processes.
5. Stabilized aqueous live-virus formulations.
6. Nasal spray devices and dose-delivery systems.
7. Methods of administering intranasal influenza vaccine.
8. Manufacturing controls that preserve infectivity and potency.

A patent review must separate expired platform patents from potentially active formulation, process, device, and method-of-use claims. Broad early patents covering cold-adapted influenza strains and live attenuated vaccine concepts may have expired or be approaching expiry, while later filings could cover specific manufacturing or formulation improvements.

Is FluMist listed in the Orange Book?

FluMist is a biologic licensed under a BLA, not a conventional small-molecule drug approved under an NDA. It therefore does not fit the standard Orange Book patent-certification pathway used for generic drug applications. The product’s competitive position is governed primarily by biologics licensing, vaccine manufacturing capability, regulatory comparability, intellectual property, and supply capacity rather than by an Abbreviated New Drug Application Paragraph IV process.[1,2]

When does FluMist Quadrivalent lose exclusivity?

FluMist does not have a single small-molecule patent cliff. Its exclusivity profile is layered across regulatory exclusivity, patents, manufacturing know-how, strain-specific technology, device rights, and supply arrangements.

Exclusivity layer	Relevance to FluMist
BLA approval	Establishes the licensed product and manufacturing controls
Biologic exclusivity	Depends on the applicable reference-product and follow-on biologic framework
Patent protection	May cover strains, attenuation, formulations, processes, devices, and methods
Trade secrets	Include cell or egg propagation controls, potency testing, and process parameters
Seasonal composition	Creates recurring regulatory and manufacturing requirements
Distribution scale	Creates a practical barrier independent of patent expiry
Pediatric and self-administration labeling	Can preserve commercial differentiation even after technical entry

FDA approval of self- or caregiver-administration for FluMist in 2024 expanded the product’s commercial reach beyond administration by a healthcare professional.[3] That regulatory change does not create indefinite exclusivity, but it increases the value of the existing delivery system and may raise the commercial hurdle for competing intranasal vaccines.

What commercial opportunities exist for FluMist excipients?

Gelatin-free reformulation

A gelatin-free version could address consumers who avoid animal-derived ingredients. Candidate stabilizers include recombinant proteins, plant-derived hydrocolloids, amino-acid systems, polysaccharides, or combinations of sucrose and non-animal protein stabilizers.

The development challenge is maintaining live-virus potency through the full shelf life without increasing viscosity, nasal irritation, or spray variability. A gelatin-free formulation could support differentiated claims, but it would require a complete comparability package and potentially a supplemental biologics application.

Egg-protein reduction

FluMist manufacturing has historically involved egg-based propagation, and the label identifies residual egg proteins. A transition to cell-based or other non-egg production could create a separate commercial proposition, particularly for consumers and providers seeking non-egg influenza vaccination.

The opportunity is broader than an excipient change. It would involve changes in upstream production, impurity profiles, analytical methods, process validation, and potentially clinical or immunogenicity comparability.

Thermostability and cold-chain reduction

The highest-value formulation opportunity is likely improved temperature stability. FluMist is distributed under refrigerated conditions. A formulation that tolerates longer controlled-temperature excursions could reduce waste, simplify pharmacy and employer distribution, and improve access in markets with limited cold-chain infrastructure.

Possible approaches include:

• Higher glass-transition stabilizer systems.
• Trehalose or alternative disaccharide systems.
• Amino-acid and sugar combinations.
• Lyophilized or partially dried live-virus formats.
• Improved container closure and oxygen-control systems.
• Spray-device designs with lower residual volume.

Lyophilization would create substantial technical risk because reconstitution could damage infectivity or make the product impractical for rapid administration. A concentrated, ready-to-use formulation with improved excursion stability may be commercially more attractive.

Preservative-free multi-dose systems

FluMist is already supplied as a preservative-free single-use spray. A preservative-free, multi-dose platform could reduce packaging and distribution costs but would create microbiological-control and device-validation requirements. Because the product contains live virus, antimicrobial preservatives could damage potency or complicate safety assessment.

Improved nasal tolerability

Nasal irritation, congestion, and rhinorrhea can affect acceptance, particularly in children. Excipient optimization could target:

• Lower osmolality.
• Reduced buffer concentration.
• Lower spray volume.
• Reduced viscosity.
• Reduced residual excipient burden.
• Improved droplet-size distribution.

The commercial value would depend on whether tolerability improvements increase completion rates or preference relative to injectable influenza vaccines.

How does FluMist compare with injectable influenza vaccines?

Attribute	FluMist Quadrivalent	Injectable inactivated or recombinant vaccines
Route	Intranasal	Intramuscular
Needle required	No	Usually yes
Active material	Live attenuated virus	Inactivated virus, subunit, or recombinant antigen
Cold-chain sensitivity	Important	Important, but product-specific
Administration setting	Clinic, pharmacy, school, employer, home under authorized use	Clinic, pharmacy, employer, other healthcare settings
Main formulation challenge	Preserve infectivity	Preserve antigen structure and sterility
Key excipient concerns	Viral stabilization, nasal tolerability, residual egg proteins, gelatin	Adjuvants, surfactants, buffers, preservatives
Competitive advantage	Needle-free administration and potential convenience	Broad age coverage and established provider workflow
Main limitation	Restrictions for certain populations and live-virus handling	Injection burden and administration requirements

FluMist’s strongest differentiator is delivery rather than a novel chemical excipient. An excipient improvement is commercially valuable when it reinforces the nasal, needle-free, convenient-use proposition.

What is the FDA regulatory status of FluMist Quadrivalent?

FluMist was initially approved in the United States in 2003. The quadrivalent formulation was approved in 2012. FDA later expanded the indicated population and, in 2024, approved self- or caregiver-administration for eligible individuals aged 2 through 49 years, subject to the product labeling and administration requirements.[1,3]

The live attenuated formulation has important clinical restrictions. It is not indicated for children younger than 2 years, adults 50 years and older, pregnant individuals, or certain people with immunocompromising conditions or other contraindications identified in the prescribing information. These restrictions limit the addressable market relative to injectable influenza vaccines.

What generic or biosimilar entry risks exist?

A conventional generic substitution pathway is unlikely to be the primary competitive threat. A competing product would need to establish a licensed biologic vaccine with adequate evidence of safety, immunogenicity, potency, attenuation, manufacturing consistency, and seasonal strain performance.

The main entry models are:

1. A competing live attenuated intranasal vaccine.
2. A new intranasal non-replicating influenza vaccine.
3. A cell-based or recombinant vaccine competing on egg-free positioning.
4. An injectable vaccine with improved convenience or broader access.
5. A device-led product using an alternative needle-free delivery system.

The technical barrier is substantial because a competitor must reproduce consistent live-virus infectivity and attenuation while meeting seasonal production deadlines. The manufacturing process and analytical package may be more difficult to replicate than the disclosed excipient list.

Which companies compete with FluMist?

FluMist competes against major injectable influenza vaccine suppliers, including Sanofi, GSK, CSL Seqirus, Pfizer in selected influenza segments, and other regional manufacturers. The most direct commercial competition comes from products that can reach children, pharmacies, schools, employers, and mass-vaccination programs.

Competitive factors include:

• Age indication.
• Needle-free delivery.
• Egg-based versus cell-based production.
• Recombinant antigen technology.
• Retail pharmacy availability.
• Government procurement.
• Pediatric provider adoption.
• Shelf life and cold-chain performance.
• Seasonal supply reliability.
• Per-dose reimbursement.

A competing intranasal product would require differentiation beyond the route of administration. Gelatin-free composition, improved temperature stability, broader labeling, or easier home use would provide stronger commercial positioning.

How strong is the FluMist patent and manufacturing estate?

The FluMist estate is strongest where patent rights are combined with regulatory and manufacturing barriers. A competitor may be able to design around individual excipients, but it would still need to establish its own viable attenuated strains, production process, potency assays, delivery device, and regulatory dossier.

Protection category	Relative barrier
Basic excipients	Low to moderate; many are widely used
Buffer system	Low; design-around potential exists
Gelatin-based stabilization	Moderate; alternatives are available but require validation
Live attenuated strain technology	High
Manufacturing process	High
Potency and infectivity assays	High
Nasal spray device	Moderate
Seasonal supply capability	High
FDA-approved self-administration workflow	Moderate to high commercial barrier

The commercial moat is therefore broader than the excipient list. The highest-value assets are likely the integrated strain, process, analytical, device, and regulatory package.

What litigation and settlement risks affect FluMist?

FluMist-related risk would most likely arise from patent disputes involving attenuated influenza strains, reverse genetics, vaccine production, nasal delivery devices, formulation stabilization, or manufacturing know-how. Because FluMist is a biologic, litigation would not follow the standard generic-drug Paragraph IV pattern associated with an Orange Book-listed NDA.

No settlement agreement should be assumed from the absence of a conventional Paragraph IV record. A complete freedom-to-operate review would need to examine U.S. patents, continuations, terminal disclaimers, post-grant proceedings, European oppositions, and ownership transfers across AstraZeneca, MedImmune, academic institutions, and vaccine technology licensors.

What revenue exposure does FluMist create for AstraZeneca?

FluMist generates seasonal revenue and has strategic value in pediatric vaccination, retail pharmacy distribution, employer programs, schools, and at-home administration. The 2024 self-administration approval expands potential channels but also increases dependence on consumer marketing, retail fulfillment, digital ordering, payer coverage, and reliable seasonal inventory.

Revenue exposure is sensitive to:

• Annual influenza severity.
• Vaccine uptake.
• Pediatric vaccination rates.
• Public-health recommendations.
• Procurement contracts.
• Manufacturing yield.
• Seasonal strain changes.
• Distribution temperature excursions.
• Competition from injectable and recombinant vaccines.
• Reimbursement for pharmacy and home administration.

The largest commercial upside from excipient work would likely come from lower waste and broader distribution, not from a small reduction in ingredient cost.

Key Takeaways

• FluMist Quadrivalent uses sucrose, phosphate buffers, gelatin hydrolysate, arginine hydrochloride, monosodium glutamate, gentamicin sulfate, residual egg proteins, and water for injection.
• The excipient system protects live attenuated influenza virus and supports refrigerated nasal delivery.
• Gelatin-free stabilization and improved temperature tolerance are the clearest formulation opportunities.
• FluMist’s main competitive advantage is needle-free administration, reinforced by FDA authorization for self- or caregiver-administration in eligible individuals.
• FluMist is licensed under BLA 103782 and is not subject to the standard Orange Book Paragraph IV pathway.
• Competitive barriers depend more on live-virus strains, manufacturing know-how, analytical controls, regulatory approval, and supply capacity than on common excipients.
• A follow-on entrant would likely need a new biologics development program rather than a conventional generic application.
• The strongest commercial opportunity is an improved-stability, gelatin-free, egg-reduced or egg-free intranasal vaccine that preserves potency and simplifies seasonal distribution.

FAQs

Can FluMist excipients be replaced without a new clinical trial?

Not necessarily. A formulation change could require analytical comparability, stability, nonclinical, immunogenicity, human factors, or clinical data depending on its effect on potency, safety, delivery, or product performance.

Is FluMist preservative-free?

Yes. FluMist is supplied as a single-use, preservative-free nasal spray.[1]

Does FluMist contain gelatin?

The prescribing information identifies gelatin hydrolysate as an inactive ingredient. The source and concentration should be assessed against the current product labeling and market-specific documentation.[1]

Can a competitor use the same FluMist excipients?

Common excipients such as sucrose and phosphate buffers are generally not exclusive by themselves. A competitor would still face potential claims involving the complete formulation, live attenuated strains, manufacturing process, device, and method of use.

Would a thermostable FluMist product have major commercial value?

Yes. Improved temperature-excursion stability could reduce wastage, expand pharmacy and employer distribution, simplify home delivery, and improve access in markets with weaker cold-chain infrastructure.

References

1. U.S. Food and Drug Administration. (2024). FluMist Quadrivalent prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). FDA approves self- or caregiver-administration of FluMist for influenza vaccination. U.S. Department of Health and Human Services.

4. Centers for Disease Control and Prevention. (2024). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices. U.S. Department of Health and Human Services.